Promedius, a Korean startup specializing in AI solutions for medical diagnostics, has made remarkable advancements in the field of healthcare. While initially focusing on a broad range of applications, the company has now shifted its attention to a specific area—osteoporosis. Leveraging the power of artificial intelligence, Promedius has developed an innovative solution that enables triaging of suspected osteoporosis patients from chest X-ray images.
Traditionally, the gold standard for osteoporosis screening and diagnosis has been the DXA test. However, accessibility to this equipment has been limited. Moreover, since osteoporosis is often asymptomatic, most cases are diagnosed only after a fracture occurs. However, with the development of Promedius’ osteoporosis solution, individuals identified as suspicious for osteoporosis through the AI-powered triage system can undergo DXA bone density testing earlier, leading to timely diagnosis.
Promedius recognizes the importance of addressing healthcare disparities and is committed to providing AI technologies to primary care clinics and medical facilities. By focusing on X-ray imaging, the company aims to bridge the gap in medical resources and improve healthcare outcomes for patients.
In pursuit of its mission, Promedius has actively pursued global partnerships. These collaborations primarily involve major DXA equipment manufacturers and global pharmaceutical companies specializing in osteoporosis treatments. By aligning with these industry leaders, Promedius aims to further advance its osteoporosis solution and expand its global presence.
With prior funding of $2 million secured from prominent investors like The Big Bang Angels and Korea Credit Guarantee Fund, Promedius has already established a strong foundation. The company is currently seeking an additional $10 million to fuel its growth and expand its global footprint.
At the core of Promedius is Dr. Hyun-Jin Bae, a highly accomplished individual with a Ph.D. background in image processing, data analysis, and big data. Their expertise and contribution to the medical imaging lab have greatly propelled the company’s trajectory.
AI Solutions for Preventive Healthcare Attracts Funding
In March 2024, Promedius secured Series A2 round investment totaling 11.2 billion won ($8.5 million), bringing its cumulative investment to 13.6 billion won ($10.8 million). Led by Starset Investment, specialized in bio-healthcare, the funding round saw participation from Korea Investment Partners, Woori Venture Partners, Crit Ventures, DK Medical, and Big Move Ventures, the CVC of Bumin Hospital.
Originating from Asan Medical Center’s Medical Imaging Intelligence Realization Lab, Promedius specializes in AI technology for automatically analyzing a patient’s osteoporosis risk using chest X-ray images. Their approach aims to prevent fractures through early detection and management.
CEO Bae Hyun-jin expressed enthusiasm for advancing AI solutions in musculoskeletal and metabolic diseases, emphasizing their vision of “Delaying aging through AI” and commitment to global implementation. This investment underscores industry trust in Promedius’ innovative direction and growth potential.
As the global demand for accurate and efficient medical diagnostics continues to rise, Promedius stands at the forefront of innovation, harnessing the potential of AI to redefine osteoporosis analysis. Through its comprehensive imaging modality approach, strategic partnerships, and visionary roadmap, Promedius is poised to make a significant impact in the healthcare sector, ultimately improving patient care worldwide.
Also Read,
- InHandPlus Unveils Doctor on Wrist: AI-Powered Smartwatch Redefining Personalized Healthcare
- Livestock Tech Startup AIDKOREA wins bronze at the 2023 Edison Awards for its Farmsplan digital healthcare solution
- Korean startup Lunit partners with UAE’s largest healthcare network, SEHA, to test AI-based radiology
- ichrogene: A Korean startup that offers free DNA trait analysis for better healthcare
- Korean healthcare startup AIRS Medical raises $20 million in Series B funding
Keep tab on latest news in the Korean startup ecosystem & follow us on LinkedIN, Facebook, and Twitter for more exciting updates and insights.
